MAP2K7 and lung cancer: All the above public evidence was in accordance with our findings in the current study, which convincingly supported our ultimatums that MKK7 p.Glu116Lys rare variant exerted adverse effects on lung cancer risk, progression and prognosis by modulating a number of cancer-related genes.